Classys launches Shurink Home beauty device line on US platforms
Medical aesthetics manufacturer Classys launched its Shurink Home device brand in the United States listing the Zap Pore Shot on Amazon and TikTok
SEOUL, South Korea, Oct. 15, 2026 - CLASSYS Inc., a Korea-based global medical aesthetics company, has officially launched its home beauty device brand, SHURINK HOME, in the United States on October 6. The first product to be offered in the U.S. is ZAP PORE SHOT, available on Amazon and TikTok Shop. This launch comes after successful early introductions in Korea and Japan.
ZAP PORE SHOT has already exceeded 6,000 pre-orders before its U.S. debut and topped the Beauty Device category on Qoo10 Japan's Mega Wari, indicating strong consumer demand before its global rollout. As K-beauty continues to influence worldwide beauty trends, the focus is shifting from Korean skincare products to the full K-Clinic experience and the technologies powering Korea's advanced aesthetic treatments.
SHURINK HOME aims to bring this next generation of K-Clinic innovation to everyday skincare routines, offering professional-grade aesthetic technology in effective, user-friendly home solutions. Unlike conventional beauty devices, SHURINK HOME is underpinned by CLASSYS' 19 years of medical aesthetics expertise and the technology behind SHURINK, Korea's #1 HIFU lifting device brand, known globally as Ultraformer.
Currently used in approximately 7.9 million treatments annually worldwide, CLASSYS' technologies are performed about once every 3.9 seconds. SHURINK HOME's technology is a direct result of this extensive experience, translating it into at-home beauty devices that provide visible and measurable results for consumers. The company currently offers energy-based aesthetic devices in over 80 countries, with cumulative sales expected to exceed 50,000 units this year.
The introduction of SHURINK HOME signifies CLASSYS' transition from professional medical aesthetics to the global consumer beauty market. ZAP PORE SHOT, the brand's initial U.S. product, is an all-in-one multi-target home pore care device designed to tackle excess sebum, loss of firmness, and uneven skin texture with a single handheld tool.
At its core, ZAP PORE SHOT utilizes SHURINK HOME's proprietary PoreSync™ Wave Technology, which integrates electroporation, micro-vibration, and LED technology. During a five-minute session, the device delivers around 37,500 micro-vibrations and 2.7 million precise pore shots. The device is meant to be used with SHURINK HOME skincare products, like the ZAP PORE BLUE PEPTIDE SERUM, to create a comprehensive at-home beauty routine that combines technology with targeted skincare.
Clinical testing by P&K Skin Research Center showed that using ZAP PORE SHOT with the brand's Toning Booster Shot Ampoule resulted in a 324% greater improvement in pore appearance compared to manual application, according to CLASSYS. CLASSYS is expanding its global footprint based on its success in Korea and Japan, planning to bring SHURINK HOME to the U.S. through Amazon and TikTok Shop.
The launch is supported by localized content, collaborations with creators, and digital marketing aimed at directly engaging beauty consumers. The U.S. launch is the first step in SHURINK HOME's broader global expansion, which includes plans for further growth in Europe, Latin America, and the Middle East, while also continuing to develop more at-home beauty devices and complementary skincare products.
Speaking about the launch, CLASSYS CEO Joon Oh Yoon stated, "The U.S. launch marks the beginning of bringing CLASSYS' 19 years of technology and expertise, built alongside medical aesthetic professionals around the world, into consumers' everyday lives." Building on the momentum already established in Korea and Japan, CLASSYS aims to accelerate its global expansion and transform home beauty into a significant growth engine for the company, extending its competitive edge from the B2B medical aesthetics market to the B2C consumer market.
Written by urgent.news from Vietnam Investment Review's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.